Zhejiang East Asia Pharmaceutical , Ltd. PEG Ratio

Zhejiang East Asia Pharmaceutical , Ltd. (605177.SS) currently reports a PEG ratio of -7.25. That is below the Healthcare sector average of 0.46. Use the charts on this page to explore Zhejiang East Asia Pharmaceutical , Ltd.'s PEG ratio history and peer comparisons.

Zhejiang East Asia Pharmaceutical , Ltd.'s PEG ratio of -7.25 is lower than the Healthcare sector average of 0.46. That is roughly 1664.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The PEG ratio is a valuation multiple that relates Zhejiang East Asia Pharmaceutical , Ltd.'s market price to a fundamental measure such as earnings, sales, or book value. At -7.25, 605177.SS can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current PEG ratio of -7.25, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 0.46. From there, open related valuation or income-statement pages for Zhejiang East Asia Pharmaceutical , Ltd., and consider following 605177.SS for alerts when major investors trade the stock.

Zhejiang East Asia Pharmaceutical , Ltd. is classified in the Healthcare sector. On PEG ratio, it currently shows -7.25 versus a sector average near 0.46. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 605177.SS with unrelated industries.